Search results for #SABCS22
WATCH: @hoperugo, of @UCSFCancer, reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022. #SABCS22 #bcsm onclive.com/view/capivaser…
@AdrianaKahnMD @maryam_lustberg @SoMeCME ER-low, HER2-neg BC have long been suspected to behave more like TNBC ➡️ KN756 data also supports this Our #SABCS22 NCBD analysis suggests pCR rates in both ER 10% or less and ER < 30% tumors are likely to be closer to those see with TNBC @sardesai_sagar aacrjournals.org/cancerres/arti…
An exploratory analysis of the #PACE trial presented at #SABCS22 showed near doubling of the PFS and OS in the metastatic setting in heavily pretreated patients that received #palbociclib, #avelumab and endocrine therapy
Throwback to #SABCS22 @OncoAlert 🚨is definitely ready for #SABCS23 ‼️ @matteolambe @aftimosp @E_de_Azambuja @NicoleKuderer @FAndreMD @prat_aleix @DrSGraff @jesusanampa @StoverLab @curijoey @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg…
Throwback to #SABCS22 @OncoAlert 🚨is definitely ready for #SABCS23 ‼️ @matteolambe @aftimosp @E_de_Azambuja @NicoleKuderer @FAndreMD @prat_aleix @DrSGraff @jesusanampa @StoverLab @curijoey @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg…
📣October is Breast Cancer Awareness Month 📅 Check out this interview with @PTarantinoMD from #SABCS22, where he discusses the remaining questions surrounding HER2-low breast cancer – how low can you go? ➡️ow.ly/OU8p50PPN81🎥 #BCSM
Stay tuned! Through the summer we’ll share insights from our Black Wo(Men) Speak Symposium, held in conjunction with #SABCS22, on ways to improve access to clinical trials for Black women & men living with MBC: mbca.me/44GLKRk #BWSS #BlackWomenSpeak
@TumorBoardTues @drsarahsam @MPishvaian @JohnEbbenMDPhD @darioT_ @curijoey @PTarantinoMD @ArielleMedford @prat_aleix @christeeny513 @TBlackburn25 @matteolambe @maur_jmp @oesterreichs @CCortiMD @khewittmd @laura_huppert @amybeumer @JaniceTNBCmets @ASridharMD @masreya_dr @ramsedhom @RodriguezGIMD @DrAmyComander @antoinedardenn1 @AnnPartridgeMD @Dr_RShatsky @jhaveri_komal @DrGattiMays @nlinmd @prarthnavb @DrTimothyErick @SemberQuinne @LEForrest @DrSGraff @KoontzOncology @AdrianaKahnMD @quirogad @vandanaraman @RenataArakelian @DFCI_BreastOnc @ErikaHamilton9 @TuftsMedicalCtr @ThanksCancer @TariKingMD @DrJamesJakub @SheydaDoc @NicoleKuderer @dradityabardia 11/17 #TumorBoardTuesday #SABCS22 ✨EMERALD✨ post hoc analysis: ❗without ESR1 mutations + PD <6mos on CDK4/6 inhibitor = elacestrant ⬆️ PFS (5.3 vs 1.9m) ❗without ESR1 mutations + PD >6mos on CDK4/6 inhibitor = elacestrant ↔️ PFS (1.9 vs 2 m) #ASCO23 #VirginiaKalkamani
@TumorBoardTues @drsarahsam @MPishvaian @JohnEbbenMDPhD @darioT_ @curijoey @PTarantinoMD @ArielleMedford @prat_aleix @christeeny513 @TBlackburn25 @matteolambe @maur_jmp @oesterreichs @CCortiMD @ehgkulow @khewittmd @laura_huppert @amybeumer @JaniceTNBCmets @ASridharMD @masreya_dr @ramsedhom @RodriguezGIMD @DrAmyComander @antoinedardenn1 @AnnPartridgeMD @Dr_RShatsky @jhaveri_komal @DrGattiMays @KalinskyKevin @chibaAkiko @stage4kelly @hmcarthur 4/17 #TumorBoardTuesday 👩🏻🏫Mini tweetorial 1👩🏻🏫 ✨MAINTAIN @KalinskyKevin 📚ascopubs.org/doi/abs/10.120… ✨PACE #SABCS22 @elmayermd 📚@LGerratana’s PACE tweet x.com/lgerratana/sta… ✨PALMIRA #ASCO23 #LoombartCussac 📚@PTarantinoMD’s PALMIRA tweet x.com/ptarantinomd/s…
@TumorBoardTues @drsarahsam @MPishvaian @JohnEbbenMDPhD @darioT_ @curijoey @PTarantinoMD @ArielleMedford @prat_aleix @christeeny513 @TBlackburn25 @matteolambe @maur_jmp @oesterreichs @CCortiMD @ehgkulow @khewittmd @laura_huppert @amybeumer @JaniceTNBCmets @ASridharMD @masreya_dr @ramsedhom @RodriguezGIMD @DrAmyComander @antoinedardenn1 @AnnPartridgeMD @Dr_RShatsky @jhaveri_komal @DrGattiMays @KalinskyKevin @chibaAkiko @stage4kelly @hmcarthur 4/17 #TumorBoardTuesday 👩🏻🏫Mini tweetorial 1👩🏻🏫 ✨MAINTAIN @KalinskyKevin 📚ascopubs.org/doi/abs/10.120… ✨PACE #SABCS22 @elmayermd 📚@LGerratana’s PACE tweet x.com/lgerratana/sta… ✨PALMIRA #ASCO23 #LoombartCussac 📚@PTarantinoMD’s PALMIRA tweet x.com/ptarantinomd/s… https://t.co/41RfNcJori
@IlanaSchlam @drsarahsam @MPishvaian @JohnEbbenMDPhD @dradityabardia @ArielleMedford @LGerratana @StoverLab @AndreaMaliachi @elmayermd @hoperugo @kevinpunie @FAndreMD @KalinskyKevin @SusanGKomen @FilippoMontemu1 @mabelonc @drteplinsky @PTarantinoMD @MridulaGeorgeMD @mfrimawi @FernandoOnco @stolaney1 @maryam_lustberg @CharlesMilrod @OncBrothers @awolff @jane_meisel @DrGattiMays #SABCS22 & #ASCO23 brought more study data &💥developments💥 in #BreastCancer 💥Join @IlanaSchlam @drsarahsam Tues 06.27.23 at 8pm ET as they 🗣️ to help #TumorBoardTuesday disseminate more about tx for patients while on a CDK4/6i 💥Earn CME @DFCI_BreastOnc @TuftsMedicalCtr
Become an IBC patient advocate by taking the IBC Learning Academy. As you can see from this post from SABCS patient advocates play a large roll in research. ibclearningacademy.org facebook.com/talkibc/posts/… #SABCS22 #inflammatorybreastcancer
Breast Cancer Prevention in Premenopausal Women: Adetunji T. Toriola, recipient of the 2022 @AACR Outstanding Investigator Award for Breast Cancer Research, addressed this topic in his award lecture at #SABCS22. View the lecture: bit.ly/3X1GDZF
Quantitative Medicine for Breast Cancer Patients: Charles M. Perou addressed this topic in his 2022 @AACR Distinguished Lecture in Breast Cancer Research at #SABCS22. View the lecture: bit.ly/42v8ulY
Metastatic breast cancer survivors Stephanie Walker, BSN, and Christine Hodgdon, MS, closed by sharing their perspectives as patients. We thank all cancer survivors for their wisdom and strength. 4/4 bit.ly/3quR3EF #NCSD2023 #SABCS22 @faceofstage4 @christeeny513
.@fumikochino discussed “Financial toxicity”: 3/4 bit.ly/43o8aH5 #NCSD2023 #SABCS22
Abbey Kaler, NP, addressed “Support for patients with MBC”: 2/4 bit.ly/3oONDwk #NCSD2023 #SABCS22
Today is National Cancer Survivors Day. During #SABCS22, Anne Blaes, MD, moderated an Educational Session on Living with Metastatic Breast Cancer that featured the following presentations: @Tara_KaufmannMD discussed “Early palliative care”: 1/4 bit.ly/3qoGbse #NCSD2023
I don't think one has to read much into early OS trend in $NVS NATALEE yet vs $LLY MonarchE, but at latest cutoff (prez at #SABCS22), the OS HR in MonarchE was 0.929 [0.748;1.153] whereas the OS HR point estimate is 0.759 [0.539;1.068] in NATALEE. I guess it would be surprising
I don't think one has to read much into early OS trend in $NVS NATALEE yet vs $LLY MonarchE, but at latest cutoff (prez at #SABCS22), the OS HR in MonarchE was 0.929 [0.748;1.153] whereas the OS HR point estimate is 0.759 [0.539;1.068] in NATALEE. I guess it would be surprising
